AstraZeneca PLC has returned to its strategy of offloading non-core assets and teamed up again with Covis Pharma to find a new home for the respiratory drugs Eklira and Duaklir.
AstraZeneca Rejigs Respiratory Franchise With Fresh Covis Deal
Licenses Out Eklira and Duaklir For $270m
Having got hold of two COPD drugs from Spain's Almirall in 2014, AstraZeneca has passed Eklira and Duaklir onto old partner Covis Pharma as it focuses on more targeted respiratory therapies.
More from Respiratory
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
Paratek agrees to acquire Optinose in a “take-private” deal valued at $330m, adding chronic rhinosinusitis product Xhance to its antibiotic Nuzyra.
• By
A Phase IIa trial studying Haduvio for the treatment of refractory chronic cough showed a benefit for patients, opening the door to a broad market and impressing investors.
• By
Complete datasets on Tezspire and depemokimab caught the eye at the AAAAI/WAO meeting in San Diego and while the AstraZeneca/Amgen drug appears to be more efficacious, the GSK candidate offers greater convenience.
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.